Stay ahead in 2026 with the latest biotech deals. Discover key collaborations, M&A, and strategic moves shaping the industry's future. Explore the pulse of biotech deals on our dedicated page, featuring only the most notable news of 2026. We meticulously curate and categorize the latest collaborations and M&A activities, ensuring you stay informed about the most significant trends and strategic moves shaping the industry. Looking for new funding opportunities and partnerships?

Original title: “2026 biotech deals tracker: the latest partnerships and M&A”

Chan Zuckerberg Initiative's Biohub will offer new grants to the rare disease community while expanding its AI drug repurposing partnership with Every Cure. The announcement also expands Biohub's partnership with Every Cure, the nonprofit founded by Dr. David Fajgenbaum that uses artificial intelligence to identify opportunities to repurpose existing medicines for diseases with few or no treatment options. Biohub already serves as a foundational philanthropic backer of Every Cure. Malepati said the money helped establish research partnerships and organize the patient and scientific communities around CACANA1A-related disorders, a group of rare, lifelong neurological and genetic conditions. The program is also expanding its partnership with Every Cure, connecting advocacy organizations with AI-identified opportunities to repurpose existing medicines. "I'm thrilled about our expanded partnership — from an initial grant to get started with building our AI platform in 2023, to where we are now," Fajgenbaum said.

Original title: “Chan Zuckerberg Initiative's Biohub to open new rare disease funding round”

The National Cancer Institute (NCI) seeks licensees for a tumorigenic cell line, A1847, from a patient with metastatic ovarian cancer. As a BRCA1 deficient cell line, it serves as a model to researchers studying cell cycle regulation, tumor suppression and effective drugs aiding in repair of DNA damage.

Original title: “Government Owned Inventions Available for License: Establishment and Characterization of the A1847 Human Ovarian Carcinoma Line”

Neumora Therapeutics is laying off 35% of workers after its most advanced asset failed a pair of Phase 3 studies, sending the biotech’s stock spiraling early Monday.

Original title: “Neumora discards depression asset, lays off staffers after pair of late-stage flops”

Sanofi makes no mention of the Commissioner’s National Priority Voucher. Tzield was awarded the ticket in October 2025, but Sanofi requested withdrawal from the program after former CDER head Tracy Beth Høeg reportedly expressed skepticism of the drug.

Original title: “Sanofi wins type 1 diabetes nod for Tzield after requesting to revoke CNPV”

For the ~1 in 100 people living with celiac, the burden of disease extends far beyond their plate.

Original title: “Celiac disease is entering a new era of therapeutic innovation”

For sterile injectables, key early decisions can have a significant impact on the products’ development.

Original title: “Planning a successful pivot from lab to clinic”

Intellia Therapeutics's Senior Vice President Maria Natale discusses why the most successful launches are shaped long before approval, with strategy, structure and patient insight at the core.

Original title: “The commercial launch playbook: Team structure, readiness and execution”

The National Institute on Aging (NIA) seeks research co- development partners and/or licensees for the pre-clinical and clinical development of the compounds as anti-inflammatory therapeutics for systemic and neurodegenerative disorders.

Original title: “Government Owned Inventions Available for License: Fluorophthalimides as Anti-Inflammatory Agents for Systemic and Neurodegenerative Disorders”

The National Institute on Aging (NIA) seeks research co- development partners and/or licensees for the pre-clinical and clinical development of the compounds as anti-inflammatory therapeutics for systemic degenerative and neurodegenerative disorders.

Original title: “Government Owned Inventions Available for License: 4-Amino-2-(Piperidin-3-yl)Isoindoline-1,3-Diones as Anti-Inflammatory Agents for Systemic Degenerative and Neurodegenerative Disorders”